MDGL vs XLI
Madrigal Pharmaceuticals Inc (MDGL) versus XLI (XLI) — a side-by-side from cached financials, not a winner call.
Madrigal Pharmaceuticals Inc (MDGL) is a biotechnology company listed on NASDAQ.
XLI (XLI) common stock.
Latest reported MDGL revenue for 2026-06-30 was $675.6M. Net income was -$152.3M. MDGL currently screens at market cap $11.56B.
XLI does not have a complete income-statement cache yet.
MDGL currently screens at market cap $11.56B. XLI currently screens at market cap $0.
Not investment advice. Open the MDGL and XLI stock pages for the full models.
Not investment advice.